Hjem › Tripelnegativ brystkreft › North Carolina › Durham
Kliniske studier for Tripelnegativ brystkreft i Durham, NC
12 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Durham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- Duke University, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RekruttererFase 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi unna
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RekruttererFase 3
- Duke Cancer Institute, Durham
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
RekruttererFase 2
- Duke University, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RekruttererFase 2/3
- Duke Cancer Institute, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RekruttererFase 2
- Duke University Medical Center, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
RekruttererFase 1
- University of North Carolina, Chapel Hill · 10 mi unna
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RekruttererFase 1
- Duke Cancer Institute /ID# 276267, Durham
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RekruttererFase 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
RekruttererFase 2
- University of North Carolina, Chapel Hill · 10 mi unna
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
RekruttererFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
A Study of NX-1607 in Adults With Advanced Malignancies
RekruttererFase 1
- University of North Carolina, Chapel Hill · 10 mi unna
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Durham
- Brystkreft64 studier
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft39 studier
- Multipelt myelom37 studier
- Akut myelogen leukemi33 studier
- Metastatisk kreft33 studier
- Prostatakreft32 studier
- Lungekreft32 studier
- Kolorektal kreft28 studier
- Eggstokkreft27 studier
- Kronisk lymfatisk leukemi27 studier
- Hjertesvikt26 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.